One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Profound Medical Corp. logo
Profound Medical Corp. PROF
$ 5.55 -1.77%
report update icon

Quarterly report 2026-Q2
added 08-06-2026

Profound Medical Corp. Income Statement 2025-2011 | PROF

Brief overview of profit and loss at Profound Medical Corp.

The comparison covers a five-year financial horizon. Revenue reported by Profound Medical Corp. was 7.3 million dollars at the beginning of the period and 16.1 million dollars at the end. The total change was +120.4%, with a CAGR of approximately 17.1%. Revenue followed a strong upward trend without signs of stagnation.

Gross profit changed from 3.5 million dollars to 11.4 million dollars (+228%). The relationship between sales and direct costs improved over the period. At the margin level, the figure shifted from 47.6% to 70.8%. Improving gross profitability strengthens the quality of revenue growth.

The five-year EBITDA result moved by −116.7%: from −$18.9 million to −$40.9 million. Changes in revenue did not translate into comparable EBITDA performance. At the operating-margin level, the figure shifted from −258.3% to −254%. The increased EBITDA share is a positive sign.

The net financial result changed from −$21.6 million to −$42.6 million. The period ended with a larger loss than it began with.

Over the period, capitalization shifted from 228 million dollars to 166 million dollars (−27.2%). Capitalization lags the underlying business improvement.

Financial takeaway

The current trajectory does not yet confirm a sustainable recovery. The positive side is supported by revenue expansion, a stronger gross margin and positive operating leverage. Caution is warranted because of declining net profitability, a weaker market valuation and a low EBITDA margin. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.

Annual Income Statement Profound Medical Corp.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

166 M 185 M 173 M 183 M 230 M 228 M 121 M 88.1 M - - - - - - -

Shares

30.2 M 24.8 M 21.2 M 20.8 M 20.5 M 11.1 M 11.1 M 10 M - - - - - - -

Historical Prices

5.49 7.45 8.18 8.78 11.2 20.6 10.9 - - - - - - - -

Net Income

-42.6 M -27.8 M -28.3 M -28.7 M -30.7 M -21.6 M -20.2 M -20.8 M -18.8 M -12.1 M -11.8 M -8.2 M - - -

Revenue

16.1 M 10.7 M 7.2 M 6.68 M 6.87 M 7.3 M 4.17 M 2.6 M 4.9 M - - - - - -

Cost of Revenue

4.7 M 3.64 M 2.89 M 3.66 M 3.92 M 3.83 M 1.78 M - - - - - - - -

Gross Profit

11.4 M 7.04 M 4.31 M 3.02 M 2.95 M 3.47 M - - 1.87 M - - - - - -

Operating Income

-41.3 M -33.1 M -28.7 M -32.1 M -30.3 M -18.9 M -14.9 M - - - - - - - -

Interest Expense

- - 146 K 290 K 448 K - - - - - - - - - -

EBITDA

-40.9 M -32.4 M -27.9 M -32.1 M -30.3 M -18.9 M -14.9 M - -17.2 M -11.4 M -9.39 M -6.18 M - - -

Operating Expenses

52.6 M 40.1 M 33 M 35.1 M 33.2 M 22.3 M 17.3 M 21 M 19.5 M - - - - - -

General and Administrative Expenses

32.1 M 23.1 M 9.17 M 9.46 M 10.3 M 7.56 M 7.68 M 6.66 M 5.94 M 4.2 M 4.39 M 1.95 M - - -

All numbers in USD currency

Quarterly Income Statement Profound Medical Corp.

2026-Q2 2026-Q1 2025-Q3 2025-Q2 2025-Q1 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

36.4 M 36.3 M 30.1 M 30.1 M 30 M 21.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-9.54 M -7.05 M -7.98 M -15.7 M -10.7 M -28.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Revenue

2.48 M 5.34 M 5.29 M 2.21 M 2.62 M 7.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cost of Revenue

536 K 1.5 M 1.36 M 593 K 768 K 2.82 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

1.95 M 3.83 M 3.93 M 1.62 M 1.85 M 4.38 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-11.1 M -8.02 M -8.91 M -13.8 M -11.2 M -28.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

- - - - - 146 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-10.9 M -7.93 M -8.82 M -13.7 M -11 M -28.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Expenses

13 M 11.9 M 12.8 M 15.4 M 13 M 33 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

7.36 M 6.59 M 7.43 M 9.33 M 8.21 M 9.17 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

The income statement is one of the three key financial reports of a company Profound Medical Corp. (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Medical devices industry

Issuer Price % 24h Market Cap Country
Orthofix Medical Orthofix Medical
OFIX
$ 9.7 -1.12 % $ 384 M curacaoCuracao
TransMedics Group TransMedics Group
TMDX
$ 71.03 0.41 % $ 2.41 B usaUSA
Aethlon Medical Aethlon Medical
AEMD
$ 5.05 1.78 % $ 3.4 M usaUSA
AxoGen AxoGen
AXGN
$ 38.31 0.64 % $ 1.76 B usaUSA
Nevro Corp. Nevro Corp.
NVRO
- - $ 217 M usaUSA
Venus Concept Venus Concept
VERO
- - $ 726 K usaUSA
Eargo Eargo
EAR
- - $ 10.2 M usaUSA
Sientra Sientra
SIEN
- -16.59 % $ 10.3 M usaUSA
Silk Road Medical, Inc Silk Road Medical, Inc
SILK
- - $ 1.07 B usaUSA
Surgalign Holdings Surgalign Holdings
SRGA
- -32.98 % $ 1.68 M usaUSA
Butterfly Network Butterfly Network
BFLY
$ 6.78 0.37 % $ 1.68 B usaUSA
Cardiovascular Systems Cardiovascular Systems
CSII
- 0.15 % $ 844 M usaUSA
ShockWave Medical ShockWave Medical
SWAV
- - $ 12.3 B usaUSA
Inari Medical Inari Medical
NARI
- - $ 4.23 B usaUSA
Abiomed Abiomed
ABMD
- - $ 17.2 B usaUSA
Allied Healthcare Products Allied Healthcare Products
AHPI
- 3.58 % $ 2.21 M usaUSA
Titan Medical Titan Medical
TMDI
- -26.32 % $ 19.6 M canadaCanada
Natus Medical Incorporated Natus Medical Incorporated
NTUS
- 1.94 % $ 1.05 B usaUSA
Axonics Modulation Technologies Axonics Modulation Technologies
AXNX
- - $ 3.31 B usaUSA
Avinger Avinger
AVGR
- -20.74 % $ 369 K usaUSA
ThermoGenesis Holdings ThermoGenesis Holdings
THMO
- -25.84 % $ 171 K usaUSA
Apollo Endosurgery Apollo Endosurgery
APEN
- - $ 475 M usaUSA
Talis Biomedical Corporation Talis Biomedical Corporation
TLIS
- 3.55 % $ 7.96 M usaUSA
NuVasive NuVasive
NUVA
- - $ 2.07 B usaUSA
Viveve Medical Viveve Medical
VIVE
- -15.35 % $ 1.71 M usaUSA
SmileDirectClub SmileDirectClub
SDC
- -53.45 % $ 9.71 M usaUSA
ViewRay ViewRay
VRAY
- 1.54 % $ 468 M usaUSA
CONMED Corporation CONMED Corporation
CNMD
$ 47.96 -2.48 % $ 1.49 B usaUSA
Acutus Medical Acutus Medical
AFIB
- -26.83 % $ 2.62 M usaUSA
ClearPoint Neuro ClearPoint Neuro
CLPT
$ 9.05 -1.04 % $ 256 M usaUSA
BIOLASE BIOLASE
BIOL
- -13.19 % $ 166 K usaUSA
Vapotherm Vapotherm
VAPO
- 6.72 % $ 34 M usaUSA
Delcath Systems Delcath Systems
DCTH
$ 14.66 1.66 % $ 525 M usaUSA
SeaSpine Holdings Corporation SeaSpine Holdings Corporation
SPNE
- 0.28 % $ 270 M usaUSA
Zynex Zynex
ZYXI
- - $ 21.1 M usaUSA
Conformis Conformis
CFMS
- - $ 16.4 M usaUSA
Medigus Ltd. Medigus Ltd.
MDGS
- 10.28 % $ 55.5 M israelIsrael
Cutera Cutera
CUTR
- -10.19 % $ 1.99 M usaUSA
Globus Medical Globus Medical
GMED
$ 81.12 -0.36 % $ 11 B usaUSA
Nemaura Medical Nemaura Medical
NMRD
- -17.8 % $ 2.74 M britainBritain
Neovasc Neovasc
NVCN
- - $ 111 M canadaCanada
Invacare Corporation Invacare Corporation
IVC
- - $ 24.7 M usaUSA
Integra LifeSciences Holdings Corporation Integra LifeSciences Holdings Corporation
IART
$ 12.07 1.34 % $ 925 M usaUSA
InMode Ltd. InMode Ltd.
INMD
$ 13.77 -1.43 % $ 890 M israelIsrael
Apyx Medical Corporation Apyx Medical Corporation
APYX
$ 2.41 1.69 % $ 99 M usaUSA
Accuray Incorporated Accuray Incorporated
ARAY
$ 0.12 -4.69 % $ 14.7 M usaUSA
IRadimed Corporation IRadimed Corporation
IRMD
$ 85.76 -0.12 % $ 1.09 B usaUSA
Integer Holdings Corporation Integer Holdings Corporation
ITGR
$ 126.54 -0.01 % $ 4.4 B usaUSA
Inogen Inogen
INGN
$ 7.05 -0.77 % $ 188 M usaUSA
Bruker Corporation Bruker Corporation
BRKR
$ 57.98 0.68 % $ 8.8 B usaUSA